(Q37609829)

21 August 2017

1 reference

title

Treating type 2 diabetes: incretin mimetics and enhancers (English)

1 reference

21 August 2017

0 references

Katherine E Nori Janosz

1

1 reference

21 August 2017

Kerstyn C Zalesin

2

1 reference

21 August 2017

Wendy M Miller

3

1 reference

21 August 2017

Peter A McCullough

4

1 reference

21 August 2017

publication date

1 October 2009

1 reference

Therapeutic advances in cardiovascular disease

21 August 2017

published in

1 reference

21 August 2017

volume

3

1 reference

21 August 2017

issue

5

1 reference

21 August 2017

page(s)

387-395

1 reference

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Diabetes mellitus: a hypercoagulable state

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Incretin-based therapies in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Vildagliptin: a review of its use in the management of type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

The growing problem of obesity and the heart: the plot "thickens".

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Beta cell mass in diabetes: a realistic therapeutic target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Effects of weight loss and pharmacotherapy on inflammatory markers of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

Intentional weight loss and mortality among overweight individuals with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944709341377

21 January 2018

Identifiers

DOI

10.1177/1753944709341377

1 reference

release_d3zzbcv67zbfxcjagsts34raf4

21 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/d3zzbcv67zbfxcjagsts34raf4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference